Overview

Cocrystal Pharma Presentation at the "reimagine Health Research Symposium" Features Overview of Platform Technology and Four Antiviral Case Studies

Read Press Release

Latest Financial Results

Stock Information

Nasdaq:

COCP

Price

Loading...

Change

Loading...

Mkt Cap

Loading...

Volume

Loading...
52 week Low/High Loading...
Day Low/High Loading...

Company Overview

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Legal Matters

TO: ALL OWNERS OF COCRYSTAL PHARMA, INC. F/K/A BIOZONE PHARMACEUTICALS, INC. (“COCRYSTAL” OR THE “COMPANY”) COMMON STOCK (TICKER SYMBOL: COCP) AS OF AUGUST 20, 2020, WHO CONTINUE TO OWN SUCH SHARES THROUGH DECEMBER 16, 2020.

PLEASE SEE THE DOCUMENTS LINKED BELOW

title

FINAL UPDATED NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO CURRENT COCRYSTAL STOCKHOLDERS

STIPULATION AND AGREEMENT OF SETTLEMENT